![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
A RECENT REVIEW: JAPANESE ENCEPHALITIS
Hembade Mahendra*, Gaikwad Yogesh, Lukkad Harish, Kangane Monika, Dr. Sathesh Kumar
ABSTRACT Japanese encephalitis (JE) is the most common form of viral encephalitis that appears in the form of frequent epidemics of brain fever throughout Southeast Asia, China and India. The disease is caused by a Flavivirus named Japanese encephalitis virus that is spread to humans by mosquitoes., Union health minister Ghulam Nabi Azad launched India’s first indigenously prodcued vaccine against Japanese Encephalitis (JE), a mosquito-borne viral infection that affects the central nervous system. Bharat Biotech launch of its Vero cell-derived purified inactivated JE vaccine “JENVAC™” which received the manufacturing and marketing approvals by Drug Controller General of India (DCGI). It is a fully indigenous vaccine commercialized using strain, identified, characterized, manufactured and tested in India. JENVAC is a purified Inactivated Japanese Encephalitis vaccine produced from an Indian thermally stable strain, 821564-XY.JENVAC® is indicated for the prevention of disease caused by Japanese encephalitis virus (JEV) in persons 1 year of age and older. It is a Vero cell derived, inactivated, and chromatographically purified Japanese encephalitis vaccine and is made from a thermally stable India strain, Kolar, 821564-XY. The vaccine must be administered intramuscularly. JENVAC is the first vaccine to be manufactured in the public-private partnership mode. These new candidate JE vaccines have the potential to generate long-lasting immunity at low cost. Keywords: Encephalitis, JENVAC, vaccine. [Download Article] [Download Certifiate] |